

1

## Supplementary materials

2

### 3 Suppl. Table S1

4 Potential biomarkers related to SCM, CY, Ade, Arb and All.

Mode	No.	Compound	Formula	$t_R$ (min)	Determined $m/z$
ES <sup>I+</sup>	1	L-Homocysteine <sup>a,b</sup>	C <sub>4</sub> H <sub>9</sub> NO <sub>2</sub> S	15.2	90.5073
	2	Betaine <sup>b,*</sup>	C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub>	1.5	100.0758
	3	Neurine <sup>a</sup>	C <sub>5</sub> H <sub>13</sub> NO	0.8	104.1070
	4	L-Proline <sup>a,b,*</sup>	C <sub>5</sub> H <sub>9</sub> NO <sub>2</sub>	1.2	116.0705
	5	5-Aminopentanoic acid <sup>a,b</sup>	C <sub>5</sub> H <sub>11</sub> NO <sub>2</sub>	0.8	118.0862
	6	Phenylethylamine <sup>a,b</sup>	C <sub>8</sub> H <sub>11</sub> N	14.5	122.0966
	7	D-Leucine <sup>b</sup>	C <sub>6</sub> H <sub>13</sub> NO <sub>2</sub>	1.2	132.1020
	8	L-Adrenaline <sup>a,b</sup>	C <sub>9</sub> H <sub>13</sub> NO <sub>3</sub>	1.5	166.0862
	9	L-Tyrosine <sup>b,*</sup>	C <sub>9</sub> H <sub>11</sub> NO <sub>3</sub>	1.2	182.0811
	10	L-Tryptophan <sup>a,b,*</sup>	C <sub>11</sub> H <sub>12</sub> N <sub>2</sub> O <sub>2</sub>	3.2	205.0970
	11	L-Kynurenine <sup>a,b</sup>	C <sub>10</sub> H <sub>12</sub> N <sub>2</sub> O <sub>3</sub>	6.8	250.1181
	12	Sphingosine <sup>a,b</sup>	C <sub>18</sub> H <sub>37</sub> NO <sub>2</sub>	10.8	282.2790
	13	Dihydrosphingosine <sup>a,b</sup>	C <sub>18</sub> H <sub>39</sub> NO <sub>2</sub>	12.2	284.2946
	14	Adenosine <sup>b,*</sup>	C <sub>10</sub> H <sub>13</sub> N <sub>5</sub> O <sub>4</sub>	6.5	309.1306
	15	N,N-Dimethylsphingosine <sup>a</sup>	C <sub>20</sub> H <sub>41</sub> NO <sub>2</sub>	12.2	310.3103
	16	Thromboxane A <sub>2</sub> <sup>a,b</sup>	C <sub>20</sub> H <sub>40</sub> O	13.2	338.3417
	17	Cholic acid <sup>a,b,*</sup>	C <sub>24</sub> H <sub>40</sub> O <sub>5</sub>	6.2	373.2735
	18	Cholesteryl acetate <sup>a,b</sup>	C <sub>29</sub> H <sub>48</sub> O <sub>2</sub>	13.5	429.3728
	19	LysoPC (15:0) <sup>a</sup>	C <sub>23</sub> H <sub>48</sub> NO <sub>7</sub> P	8.5	464.3132
	20	7- $\alpha$ ,27-Dihydroxycholesterol <sup>b</sup>	C <sub>27</sub> H <sub>46</sub> O <sub>3</sub>	8.5	482.3604
	21	LysoPC (16:1(9Z)) <sup>a</sup>	C <sub>24</sub> H <sub>48</sub> NO <sub>7</sub> P	7.2	494.3242
	22	LysoPC (16:0) <sup>a,b</sup>	C <sub>24</sub> H <sub>50</sub> NO <sub>7</sub> P	7.8	496.3408
	23	LysoPC (18:0) <sup>b</sup>	C <sub>26</sub> H <sub>54</sub> NO <sub>6</sub> P	8.8	508.3762
	24	LysoPE (0:0/20:0) <sup>a,b</sup>	C <sub>25</sub> H <sub>52</sub> NO <sub>7</sub> P	8.8	510.3557
	25	LysoPC (18:2 (9Z,12Z)) <sup>a,b</sup>	C <sub>26</sub> H <sub>50</sub> NO <sub>7</sub> P	7.5	520.3407
	26	LysoPC (0:0/18:0) <sup>a,b</sup>	C <sub>26</sub> H <sub>52</sub> NO <sub>7</sub> P	9.5	524.3718
	27	LysoPE (0:0/22:0) <sup>a</sup>	C <sub>27</sub> H <sub>56</sub> NO <sub>7</sub> P	10.8	538.3870
	28	LysoPC (20:4(5Z,8Z,11Z,14Z)) <sup>a,b</sup>	C <sub>28</sub> H <sub>50</sub> NO <sub>7</sub> P	7.5	544.3407
	29	LysoPC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)) <sup>b</sup>	C <sub>30</sub> H <sub>50</sub> NO <sub>7</sub> P	7.2	568.3394
	30	Ceramide 1-phosphate (d18:1/16:0) <sup>a,b</sup>	C <sub>34</sub> H <sub>68</sub> NO <sub>6</sub> P	14.2	681.4953
	31	Cardiolipin (16:1(9Z)/18:1(9Z)/16:0/16:0) <sup>a,b</sup>	C <sub>75</sub> H <sub>142</sub> O <sub>17</sub> P <sub>2</sub>	12.2	689.4939

	32	Cardiolipin (16:1(9Z)/18:0/16:1(9Z)/18:0) <sup>b</sup>	C <sub>77</sub> H <sub>146</sub> O <sub>17</sub> P <sub>2</sub>	14.2	703.5082
	33	Sphingomyelin (d18:0/14:1(9Z)(OH)) <sup>a,b</sup>	C <sub>37</sub> H <sub>73</sub> N <sub>2</sub> O <sub>7</sub> P	12.2	711.5068
	34	PA (P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) <sup>b</sup>	C <sub>43</sub> H <sub>73</sub> O <sub>7</sub> P	12.2	733.5188
	35	PE (14:0/20:3(8z,11z,14z)) <sup>b</sup>	C <sub>39</sub> H <sub>72</sub> NO <sub>8</sub> P	11.8	755.5323
	36	PA (20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)) <sup>b</sup>	C <sub>45</sub> H <sub>77</sub> O <sub>8</sub> P	11.8	777.5454
	37	PC (20:4(5Z,8Z,11Z,14Z)/16:0) <sup>b</sup>	C <sub>44</sub> H <sub>80</sub> NO <sub>8</sub> P	9.8	782.5704
ESI-	1	(R)-3-Hydroxybutyric acid <sup>b</sup>	C <sub>4</sub> H <sub>8</sub> O <sub>3</sub>	1.1	103.0402
	2	Ketoleucine <sup>b</sup>	C <sub>6</sub> H <sub>10</sub> O <sub>3</sub>	4.5	129.0557
	3	Uric acid <sup>a,b,*</sup>	C <sub>5</sub> H <sub>4</sub> N <sub>4</sub> O <sub>3</sub>	1.1	167.0210
	4	D-Glucose <sup>a,b,*</sup>	C <sub>6</sub> H <sub>12</sub> O <sub>6</sub>	1.1	201.0383
	5	Hexadecanoic acid <sup>a</sup>	C <sub>16</sub> H <sub>32</sub> O <sub>2</sub>	11.8	255.2332
	6	Linoleic acid <sup>a,b,*</sup>	C <sub>18</sub> H <sub>32</sub> O <sub>2</sub>	10.8	279.2335
	7	Oleic acid <sup>a,b,*</sup>	C <sub>18</sub> H <sub>34</sub> O <sub>2</sub>	11.8	281.2486
	8	<i>p</i> -Cresol glucuronide <sup>a</sup>	C <sub>13</sub> H <sub>16</sub> O <sub>7</sub>	5.1	283.0823
	9	Arachidonic acid <sup>a,b,*</sup>	C <sub>20</sub> H <sub>32</sub> O <sub>2</sub>	10.5	303.2337
	10	5,6-Dihydroxy-8Z,11Z,14Z-eicosatrienoate <sup>a,b</sup>	C <sub>20</sub> H <sub>32</sub> O <sub>3</sub>	8.1	319.2283
	11	Docosahexaenoic acid <sup>a</sup>	C <sub>22</sub> H <sub>32</sub> O <sub>2</sub>	10.1	327.2338
	12	Cholesterol sulfate <sup>b</sup>	C <sub>27</sub> H <sub>46</sub> O <sub>4</sub> S	14.1	465.3043
	13	LysoPC (14:0) <sup>a</sup>	C <sub>22</sub> H <sub>46</sub> NO <sub>7</sub> P	7.1	512.2998
	14	Taurocholic acid <sup>b</sup>	C <sub>26</sub> H <sub>45</sub> NO <sub>7</sub> S	5.8	514.2845
	15	LysoPC (P-18:0) <sup>b</sup>	C <sub>26</sub> H <sub>54</sub> NO <sub>6</sub> P	8.8	552.3671
	16	LysoPC (18:1(9Z)) <sup>a,b</sup>	C <sub>26</sub> H <sub>52</sub> NO <sub>7</sub> P	8.5	566.3473
	17	PA (13:0/18:4(6Z,9Z,12Z,15Z)) <sup>b</sup>	C <sub>34</sub> H <sub>59</sub> O <sub>8</sub> P	9.8	607.3735

5

6 <sup>a</sup> Metabolites obtained from SCM vs. C.

7 <sup>b</sup> Metabolites obtained from SCM vs. CY/Ade/Arb/All.

8 \* Metabolites identified by standards.

9 PA: Phosphatidate; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine;

10 LysoPC: Lysophosphatidylcholine; LysoPE: Lysophosphatidylethanolamine.

11

## 12 Suppl. Table S2

### 13 RSDs and change trends for potential biomarkers.

Mod e	No.	Compound	RSDs of retentio n times	RSDs of peak areas	SC M vs. C	CY vs. SCM	Ade vs. SCM	Arb vs. SC M	All vs. SC M
ESI <sup>+</sup>	1	L-Homocysteine <sup>a,b</sup>	0.01	4.30	↑	↑	↑	↑	↑
	2	Betaine <sup>b,*</sup>	1.42	26.96	↑	↓		↓	↓
	3	Neurine <sup>a</sup>	0.05	15.06	↓	↑	↑	↑	↑
	4	L-Proline <sup>a,b,*</sup>	0.73	12.08	↑	↓			
	5	5-Aminopentanoic acid <sup>a,b</sup>	1.00	12.78	↓			↑	
	6	Phenylethylamine <sup>a,b</sup>	0.07	3.89	↓	↓	↓	↓	↓
	7	D-Leucine <sup>b</sup>	0.43	7.14	↓	↑	↑	↑	↑
	8	L-Adrenaline <sup>a,b</sup>	0.58	5.24	↓		↑	↑	
	9	L-Tyrosine <sup>b,*</sup>	0.45	12.77	↓		↑		
	10	L-Tryptophan <sup>a,b,*</sup>	0.58	21.54	↓	↑	↑	↑	↑
	11	L-Kynurenine <sup>a,b</sup>	0.08	30.58	↑	↓	↓	↓	↓
	12	Sphingosine <sup>a,b</sup>	0.09	14.81	↓	↑	↑	↑	↑
	13	Dihydrosphingosine <sup>a,b</sup>	0.06	2.96	↑	↑	↑	↑	↑
	14	Adenosine <sup>b,*</sup>	0.08	33.84	↓			↑	↑
	15	N,N-Dimethylsphingosine <sup>a</sup>	0.08	11.00	↑	↓	↓	↓	↓
	16	Thromboxane A2 <sup>a,b</sup>	0.04	9.92	↑	↓	↓	↓	↓
	17	Cholic acid <sup>a,b,*</sup>	0.09	38.46	↑		↑		↑
	18	Cholesteryl acetate <sup>a,b</sup>	0.09	40.84	↑	↑	↑	↑	↑
	19	LysoPC (15:0) <sup>a</sup>	0.08	10.76	↓	↑	↑	↑	↓
	20	7- $\alpha$ ,27-Dihydroxycholesterol <sup>b</sup>	0.09	15.26	↓		↑		↓
	21	LysoPC (16:1(9Z)) <sup>a</sup>	0.08	14.90	↓	↑	↑	↑	↓
	22	LysoPC (16:0) <sup>a,b</sup>	0.07	8.95	↓	↑	↑	↑	↓
	23	LysoPC (18:0) <sup>b</sup>	0.08	14.33	↓		↑		↓
	24	LysoPE (0:0/20:0) <sup>a,b</sup>	0.08	18.66	↓		↑	↑	
	25	LysoPC (18:2 (9Z,12Z)) <sup>a,b</sup>	0.10	14.83	↓		↑	↑	↓
	26	LysoPC (0:0/18:0) <sup>a,b</sup>	0.07	13.42	↓	↑	↑	↑	↓
	27	LysoPE (0:0/22:0) <sup>a</sup>	0.12	8.61	↓	↑	↑	↑	↓
	28	LysoPC (20:4(5Z,8Z,11Z,14Z)) <sup>a,b</sup>	0.08	8.68	↓	↑	↑	↑	
	29	LysoPC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)) <sup>b</sup>	0.05	20.21	↓	↑	↑		↓
	30	Ceramide 1-phosphate (d18:1/16:0) <sup>a,b</sup>	0.13	9.42	↓	↓	↓	↓	↓
	31	Cardiolipin (16:1(9Z)/18:1(9Z)/16:0/16:0) <sup>a,b</sup>	0.12	10.34	↓	↓	↓	↓	↓
	32	Cardiolipin (16:1(9Z)/18:0/16:1(9Z)/18:0) <sup>b</sup>	0.16	10.29	↓	↓	↓	↓	↓

	33	Sphingomyelin (d18:0/14:1(9Z)(OH)) <sup>a,b</sup>	0.12	6.83	↓	↓	↓	↓	↓
	34	PA (P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) <sup>b</sup>	0.07	10.34	↓	↓	↓	↓	↓
	35	PE (14:0/20:3(8z,11z,14z)) <sup>b</sup>	0.04	7.49	↓	↓	↓	↓	↓
	36	PA (20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)) <sup>b</sup>	0.06	5.16	↓	↓	↓	↓	↓
	37	PC (20:4(5Z,8Z,11Z,14Z)/16:0) <sup>b</sup>	0.09	16.46	↑	↓	↓		
ESI-	1	(R)-3-Hydroxybutyric acid <sup>b</sup>	0.23	17.18	↓			↑	
	2	Ketoleucine <sup>b</sup>	0.20	17.97	↓	↑			
	3	Uric acid <sup>a,b,*</sup>	0.34	16.35	↓	↓	↓	↓	↓
	4	D-Glucose <sup>a,b,*</sup>	0.29	8.88	↑	↓	↓	↓	↓
	5	Hexadecanoic acid <sup>a</sup>	0.07	18.75	↓	↓	↓	↓	↓
	6	Linoleic acid <sup>a,b,*</sup>	0.04	14.45	↓	↓	↓	↓	↓
	7	Oleic acid <sup>a,b,*</sup>	0.05	17.20	↓			↓	↓
	8	<i>p</i> -Cresol glucuronide <sup>a</sup>	0.03	15.87	↑	↓	↓	↓	↓
	9	Arachidonic acid <sup>a,b,*</sup>	0.03	12.03	↓			↓	
	10	5,6-Dihydroxy-8Z,11Z,14Z-eicosatrienoate <sup>a,b</sup>	0.04	23.27	↓	↓		↓	
	11	Docosaehaenoic acid <sup>a</sup>	0.04	19.55	↓	↑	↑	↑	↑
	12	Cholesterol sulfate <sup>b</sup>	0.22	44.18	↑	↓	↓	↓	↓
	13	LysoPC (14:0) <sup>a</sup>	0.11	23.92	↓	↑	↑	↑	↓
	14	Taurocholic acid <sup>b</sup>	0.90	24.88	↑	↓			
	15	LysoPC (P-18:0) <sup>b</sup>	0.08	13.70	↓				↓
	16	LysoPC (18:1(9Z)) <sup>a,b</sup>	0.04	10.68	↓	↑	↑	↑	↓
	17	PA (13:0/18:4(6Z,9Z,12Z,15Z)) <sup>b</sup>	0.09	7.47	↓			↓	↓

14

15 <sup>a</sup> Metabolites obtained from SCM vs. C.


16 <sup>b</sup> Metabolites obtained from SCM vs. CY/Ade/Arb/All.

17 \* Metabolites identified by standards.

18 ↑ up-regulated

19 ↓ down-regulated


20




21

22

**Adenosine**



**Arbutin**




**Allantoin**

23


24 **Suppl. Fig. S1.** Chemical structures of adenosine, arbutin and allantoin.

25


26




27




28



29



30



31

● C group, ● SCM group, ● CY group, ● Ade group, ● Arb group, ● All group.

32 **Suppl. Fig. S2.** OPLS-DA score scatter plots and S-plots obtained from SCM and control/treatment

33 groups. C vs. SCM group (A), SCM vs. CY/Ade/Arb/All group (B-E).